+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sodium Phenylbutyrate Market by Therapeutic Indication (Cancer Supportive Therapy, Hepatic Encephalopathy, Urea Cycle Disorders), Product Form (Intravenous Injection, Oral Suspension, Oral Tablet), Route of Administration, End User - Global Forecast 2025-2030- Product Image
Sodium Phenylbutyrate Market by Therapeutic Indication (Cancer Supportive Therapy, Hepatic Encephalopathy, Urea Cycle Disorders), Product Form (Intravenous Injection, Oral Suspension, Oral Tablet), Route of Administration, End User - Global Forecast 2025-2030- Product Image
Sale

Sodium Phenylbutyrate Market by Therapeutic Indication (Cancer Supportive Therapy, Hepatic Encephalopathy, Urea Cycle Disorders), Product Form (Intravenous Injection, Oral Suspension, Oral Tablet), Route of Administration, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6137095
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Since its initial exploration in the latter half of the twentieth century, sodium phenylbutyrate has evolved from a niche therapeutic to a critical intervention in the management of urea cycle disorders. Its mechanism of diverting nitrogen waste pathways has underpinned clinical protocols aimed at reducing hyperammonemia and improving patient outcomes. Over time, advances in formulation and administration have enhanced its tolerability and accessibility for diverse patient populations.

Beyond its foundational role in rare metabolic conditions, sodium phenylbutyrate has demonstrated potential in broader applications. In hepatic encephalopathy management, it offers an alternative nitrogen scavenging approach that can mitigate neurocognitive decline. Moreover, emerging evidence supports its use as an adjunct in cancer supportive therapy, where its epigenetic modulation may enhance chemotherapeutic efficacy and reduce treatment-related toxicities.

As the pharmaceutical landscape continues to innovate, the trajectory of sodium phenylbutyrate remains closely tied to evolving clinical guidelines, patient advocacy efforts, and advances in delivery technologies. The interplay between scientific discovery and regulatory adaptation sets the stage for ongoing growth, underscoring the importance of a nuanced understanding of its developmental history and therapeutic promise.

Evolving Therapeutic Paradigms and Policy Shifts Redefining the Sodium Phenylbutyrate Landscape across Indications and Geographies

Innovation in drug delivery and an expanding therapeutic portfolio have catalyzed transformative shifts in how sodium phenylbutyrate is perceived and utilized. Technological breakthroughs in sustained-release formulations have improved patient adherence, enabling more consistent plasma levels and reducing the burden of frequent dosing. These advancements have been paralleled by clinical trials exploring novel indications, such as neurodegenerative disorders and adjunctive oncology regimens, thereby broadening the scope of its clinical impact.

Regulatory landscapes have also evolved to accommodate expedited pathways for drugs addressing orphan conditions. Streamlined review processes and incentives have accelerated the entry of next-generation phenylbutyrate formulations into key markets. Concurrently, partnerships between academic institutions and pharmaceutical developers have leveraged shared expertise and resources, driving a more collaborative environment for clinical research and post-marketing surveillance.

As patient advocacy groups gain prominence, their influence on research priorities and policy decisions has grown. Through sustained dialogue with regulators and industry stakeholders, these organizations have elevated the importance of patient-centric endpoints, such as quality of life and long-term neurological function. In turn, developers are increasingly integrating real-world evidence into their strategic frameworks, ensuring that future innovations align with the needs of both clinicians and patients.

Analyzing How the 2025 United States Tariff Adjustments Reshape Supply Dynamics, Cost Structures, and Regulatory Compliance in Sodium Phenylbutyrate

In 2025, adjustments in United States tariff policies have exerted a pronounced influence on the supply chain dynamics of sodium phenylbutyrate. Imposed duty changes on key raw materials have heightened the focus on cost management, compelling manufacturers to reassess sourcing strategies and negotiate new supplier agreements. This reconfiguration has driven greater interest in localized production facilities, as companies seek to minimize exposure to cross-border tariff volatility.

Simultaneously, compliance requirements have become more stringent, with customs authorities enforcing detailed documentation for pharmaceutical imports. The resulting administrative burden has prompted a shift towards more integrated logistics models, where stakeholders engage in proactive tariff classification and risk mitigation planning. These strategic pivots are essential for maintaining uninterrupted supply of this critical therapy.

While increased duties may introduce marginal cost increases, industry leaders are exploring value-based contracting and risk-sharing arrangements to preserve patient access. By collaborating closely with payers and healthcare providers, manufacturers can align pricing structures with therapeutic outcomes, ensuring that increased supply chain expenditures do not translate into insurmountable barriers for patients. Overall, the 2025 tariff landscape underscores the importance of agile operations and strategic foresight in navigating evolving trade policies.

Uncovering Demand Patterns through Comprehensive Segmentation across Therapeutic Indications, Product Forms, Administration Routes, and End User Settings

An in-depth examination of market dynamics reveals distinct patterns when analyzed through various segmentation lenses. Based on therapeutic indication, the domain encompasses use in cancer supportive therapy, coping with the collateral impacts of chemotherapy; hepatic encephalopathy, targeting neurotoxicity associated with liver insufficiency; and urea cycle disorders, addressing rare metabolic defects. Each of these indications presents unique clinical pathways and patient management strategies that influence product adoption and treatment protocols.

From the perspective of product form, sodium phenylbutyrate is available as an intravenous injection for acute intervention, an oral suspension suitable for pediatric and geriatric compliance, and an oral tablet offering convenience for chronic administration. These forms cater to varying patient needs and care settings, driving differential utilization across treatment environments.

Assessing the route of administration highlights two main channels: intravenous delivery for hospital or clinic settings, ensuring rapid efficacy in acute scenarios, and oral administration for outpatient management, where long-term adherence is paramount. The choice between these routes impacts not only clinical outcomes but also logistics and patient quality of life.

Finally, considering end user segmentation underscores the significance of delivery platforms such as home healthcare services, hospitals, retail pharmacies, and specialty clinics. Each channel brings its own operational considerations, reimbursement frameworks, and patient support requirements, shaping the overall market landscape.

Delving into Regional Dynamics and Growth Drivers Shaping Sodium Phenylbutyrate Adoption across the Americas, Europe Middle East Africa, and Asia Pacific Markets

The dynamics of sodium phenylbutyrate adoption vary markedly across global regions, driven by regulatory frameworks, healthcare infrastructure, and demographic trends. In the Americas, well-established reimbursement pathways and a strong focus on rare disease treatment foster a robust environment for therapy advancement. Collaboration between industry and patient advocacy groups accelerates clinical trial enrollment and post-market monitoring, bolstering confidence in treatment outcomes.

Within the Europe Middle East Africa region, diverse healthcare systems present both challenges and opportunities. Strong regulatory alignment within certain economic unions streamlines drug approvals, while other markets require tailored pricing negotiations and localized clinical evidence. Emerging markets in the Middle East and Africa are witnessing growing investment in specialized care facilities, creating new avenues for therapy access and distribution partnerships.

Turning to the Asia Pacific region, rapid urbanization and expanding healthcare coverage underpin increasing demand for advanced therapies. Countries with mature pharmaceutical sectors are prioritizing innovation and generics competition, whereas others are establishing frameworks for orphan drug programs. Across the region, strategic alliances and technology transfers are common, enabling companies to penetrate markets with varying degrees of economic complexity and regulatory maturity.

Profiling Leading Pharmaceutical Players and Their Strategic Initiatives Driving Innovation and Market Positioning in Sodium Phenylbutyrate

Key players in the sodium phenylbutyrate sector are adopting a range of strategic initiatives to reinforce their market positions. Several established pharmaceutical firms have invested heavily in research collaborations aimed at enhancing formulation stability and expanding therapeutic applications. These partnerships often involve academic institutions and contract research organizations, leveraging complementary expertise in chemistry, biology, and clinical development.

Simultaneously, biotech startups are exploring novel delivery technologies, such as nanoparticle encapsulation and targeted prodrug approaches, to improve bioavailability and reduce dosing frequencies. These innovations reflect a growing emphasis on patient-centric design and long-term adherence. In parallel, alliances between local distributors and global manufacturers facilitate broader geographic reach, ensuring that therapies are accessible in both mature and emerging markets.

Another strategic focus lies in intellectual property portfolios, with companies securing patent protections for new formulations and indications. This approach not only safeguards competitive advantages but also attracts potential licensing and merger opportunities. Collectively, these strategic moves underscore a competitive landscape where collaboration and innovation drive sustainable growth.

Strategic Imperatives for Industry Stakeholders to Capitalize on Emerging Opportunities and Mitigate Challenges in the Sodium Phenylbutyrate Sector

In light of evolving market trends and regulatory complexities, industry leaders should consider a multifaceted approach to capitalize on emerging opportunities in the sodium phenylbutyrate space. Prioritizing research into novel indications can unlock new revenue streams and address unmet clinical needs, particularly in neurological and oncology supportive contexts.

Optimizing supply chain resilience through diversified sourcing and regional production hubs will mitigate the impact of trade policy shifts. Establishing strategic stockpiles and leveraging digital tracking systems can further enhance operational agility and reduce the risk of shortages. In parallel, engaging with payers to develop outcome-based contracting models will align commercial objectives with patient value, fostering sustainable payer relationships.

Building robust patient support programs that integrate telehealth monitoring and educational resources can drive adherence and improve clinical outcomes. Such initiatives strengthen brand loyalty and generate real-world evidence that can inform future regulatory and reimbursement decisions. Finally, fostering open dialogue with regulatory bodies and patient advocacy organizations will ensure that developmental programs remain aligned with evolving guidelines and patient expectations.

Outlining the Robust Methodological Framework Combining Primary Engagements and Secondary Validation to Deliver Comprehensive Sodium Phenylbutyrate Market Insights

The research methodology underpinning this analysis combines primary and secondary data collection to ensure depth and reliability. Primary engagements include structured interviews with key opinion leaders, regulatory officials, and senior executives across pharmaceutical and healthcare organizations. These interviews provide qualitative insights into clinical adoption trends, policy developments, and strategic priorities.

Secondary research draws upon peer-reviewed journals, patent filings, clinical trial registries, and publicly available regulatory documentation. Data triangulation techniques have been employed to validate findings and reconcile discrepancies between diverse information sources. An emphasis on real-world evidence, including observational studies and patient registries, enriches the contextual understanding of therapy utilization and outcomes.

Analytical frameworks such as SWOT and PESTEL have been applied to assess internal capabilities and external environmental factors. Market segmentation analyses are grounded in clearly defined criteria, ensuring that insights reflect meaningful distinctions across therapeutic indication, product form, administration route, and end user. Rigorous editorial review and quality control processes further guarantee the accuracy and coherence of the final deliverable.

Synthesizing Key Findings and Strategic Outlooks to Empower Decision Makers in the Sodium Phenylbutyrate Landscape

In summary, sodium phenylbutyrate occupies a pivotal position within the treatment landscape for urea cycle disorders, hepatic encephalopathy, and cancer supportive therapy. Advances in formulation and regulatory pathways have redefined its potential, while evolving trade policies underscore the importance of supply chain agility. Segmentation insights highlight diverse requirements across clinical indications, product forms, administration routes, and end user environments, informing targeted strategies for market engagement.

Regional analyses reveal distinct opportunities and challenges, from established reimbursement frameworks in the Americas to emerging orphan drug initiatives in the Asia Pacific. Leading companies are engaging in collaborative research, innovative delivery development, and strategic partnerships to fortify their competitive standing. Combined, these factors form a nuanced market ecosystem that demands strategic foresight and operational resilience.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapeutic Indication
    • Cancer Supportive Therapy
    • Hepatic Encephalopathy
    • Urea Cycle Disorders
  • Product Form
    • Intravenous Injection
    • Oral Suspension
    • Oral Tablet
  • Route Of Administration
    • Intravenous
    • Oral
  • End User
    • Home Healthcare
    • Hospitals
    • Retail Pharmacies
    • Specialty Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Horizon Therapeutics plc
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Apotex Inc.
  • Viatris Inc.
  • Amneal Pharmaceuticals LLC
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Aurobindo Pharma Limited

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Surge in orphan drug incentive programs accelerating sodium phenylbutyrate adoption in urea cycle disorders
5.2. Growth of compounding pharmacy custom formulations driving product diversification for sodium phenylbutyrate therapies
5.3. Emergence of innovative oral delivery technologies enhancing sodium phenylbutyrate patient compliance in metabolic treatment
5.4. Strategic alliances between biotech innovators and generics manufacturers expanding regional sodium phenylbutyrate market coverage
5.5. Increasing clinical research into sodium phenylbutyrate repurposing for neurodegenerative disorder management and therapy development
5.6. Launch of taste-masked oral granules and improved palatability formulations to enhance sodium phenylbutyrate patient adherence in pediatrics
5.7. Impact of biosimilar entrants on sodium phenylbutyrate pricing dynamics and competitive landscape across major pharmaceutical markets
5.8. Integration of sodium phenylbutyrate with next generation ammonia scavengers in combination therapies for rare metabolic conditions
5.9. Expansion of precision medicine strategies incorporating genetic profiling for optimized sodium phenylbutyrate dosing in urea cycle disorders
5.10. Regulatory approvals of novel sodium phenylbutyrate prodrugs improving pharmacokinetics and dosing convenience for chronic metabolic patients
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Sodium Phenylbutyrate Market, by Therapeutic Indication
8.1. Introduction
8.2. Cancer Supportive Therapy
8.3. Hepatic Encephalopathy
8.4. Urea Cycle Disorders
9. Sodium Phenylbutyrate Market, by Product Form
9.1. Introduction
9.2. Intravenous Injection
9.3. Oral Suspension
9.4. Oral Tablet
10. Sodium Phenylbutyrate Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
11. Sodium Phenylbutyrate Market, by End User
11.1. Introduction
11.2. Home Healthcare
11.3. Hospitals
11.4. Retail Pharmacies
11.5. Specialty Clinics
12. Americas Sodium Phenylbutyrate Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Sodium Phenylbutyrate Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Sodium Phenylbutyrate Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Horizon Therapeutics plc
15.3.2. Teva Pharmaceutical Industries Ltd.
15.3.3. Sandoz International GmbH
15.3.4. Apotex Inc.
15.3.5. Viatris Inc.
15.3.6. Amneal Pharmaceuticals LLC
15.3.7. Hikma Pharmaceuticals PLC
15.3.8. Lupin Limited
15.3.9. Dr. Reddy’s Laboratories Ltd.
15.3.10. Aurobindo Pharma Limited
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. SODIUM PHENYLBUTYRATE MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS SODIUM PHENYLBUTYRATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS SODIUM PHENYLBUTYRATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES SODIUM PHENYLBUTYRATE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES SODIUM PHENYLBUTYRATE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SODIUM PHENYLBUTYRATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SODIUM PHENYLBUTYRATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC SODIUM PHENYLBUTYRATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC SODIUM PHENYLBUTYRATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. SODIUM PHENYLBUTYRATE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. SODIUM PHENYLBUTYRATE MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. SODIUM PHENYLBUTYRATE MARKET: RESEARCHAI
FIGURE 24. SODIUM PHENYLBUTYRATE MARKET: RESEARCHSTATISTICS
FIGURE 25. SODIUM PHENYLBUTYRATE MARKET: RESEARCHCONTACTS
FIGURE 26. SODIUM PHENYLBUTYRATE MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. SODIUM PHENYLBUTYRATE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY CANCER SUPPORTIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY CANCER SUPPORTIVE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY HEPATIC ENCEPHALOPATHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY HEPATIC ENCEPHALOPATHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY UREA CYCLE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY UREA CYCLE DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY ORAL TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY ORAL TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL SODIUM PHENYLBUTYRATE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. AMERICAS SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 42. AMERICAS SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 43. AMERICAS SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 44. AMERICAS SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 45. AMERICAS SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 46. AMERICAS SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS SODIUM PHENYLBUTYRATE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS SODIUM PHENYLBUTYRATE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 51. UNITED STATES SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 52. UNITED STATES SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 53. UNITED STATES SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 54. UNITED STATES SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 55. UNITED STATES SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 56. UNITED STATES SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 57. UNITED STATES SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 58. UNITED STATES SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES SODIUM PHENYLBUTYRATE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES SODIUM PHENYLBUTYRATE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 61. CANADA SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 62. CANADA SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 63. CANADA SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 64. CANADA SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 65. CANADA SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 66. CANADA SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 67. CANADA SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 68. CANADA SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 69. MEXICO SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 70. MEXICO SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 71. MEXICO SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 72. MEXICO SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 73. MEXICO SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 74. MEXICO SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 75. MEXICO SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 76. MEXICO SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 77. BRAZIL SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 78. BRAZIL SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 79. BRAZIL SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 80. BRAZIL SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 81. BRAZIL SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 82. BRAZIL SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 83. BRAZIL SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. BRAZIL SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. ARGENTINA SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 86. ARGENTINA SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 87. ARGENTINA SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 88. ARGENTINA SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 89. ARGENTINA SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 90. ARGENTINA SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 91. ARGENTINA SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 92. ARGENTINA SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA SODIUM PHENYLBUTYRATE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA SODIUM PHENYLBUTYRATE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 104. UNITED KINGDOM SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 106. UNITED KINGDOM SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. UNITED KINGDOM SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. UNITED KINGDOM SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. GERMANY SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 112. GERMANY SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 113. GERMANY SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 114. GERMANY SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 115. GERMANY SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 116. GERMANY SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 117. GERMANY SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. GERMANY SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. FRANCE SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 120. FRANCE SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 121. FRANCE SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 122. FRANCE SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 123. FRANCE SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 124. FRANCE SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 125. FRANCE SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. FRANCE SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. RUSSIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 128. RUSSIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 129. RUSSIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 130. RUSSIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 131. RUSSIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 132. RUSSIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 133. RUSSIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. RUSSIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. ITALY SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 136. ITALY SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 137. ITALY SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 138. ITALY SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 139. ITALY SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. ITALY SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. ITALY SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. ITALY SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. SPAIN SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 144. SPAIN SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 145. SPAIN SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 146. SPAIN SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 147. SPAIN SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 148. SPAIN SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 149. SPAIN SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. SPAIN SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 155. UNITED ARAB EMIRATES SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 156. UNITED ARAB EMIRATES SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 157. UNITED ARAB EMIRATES SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. UNITED ARAB EMIRATES SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 160. SAUDI ARABIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 162. SAUDI ARABIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 164. SAUDI ARABIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. SAUDI ARABIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 168. SOUTH AFRICA SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 170. SOUTH AFRICA SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. SOUTH AFRICA SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. SOUTH AFRICA SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. SOUTH AFRICA SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. DENMARK SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 176. DENMARK SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 177. DENMARK SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 178. DENMARK SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 179. DENMARK SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 180. DENMARK SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 181. DENMARK SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. DENMARK SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. NETHERLANDS SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 184. NETHERLANDS SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 185. NETHERLANDS SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 186. NETHERLANDS SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 187. NETHERLANDS SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 188. NETHERLANDS SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 189. NETHERLANDS SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. NETHERLANDS SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. QATAR SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 192. QATAR SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 193. QATAR SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 194. QATAR SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 195. QATAR SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. QATAR SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. QATAR SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. QATAR SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. FINLAND SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 200. FINLAND SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 201. FINLAND SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 202. FINLAND SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 203. FINLAND SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 204. FINLAND SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 205. FINLAND SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. FINLAND SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. SWEDEN SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 208. SWEDEN SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 209. SWEDEN SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 210. SWEDEN SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 211. SWEDEN SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. SWEDEN SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. SWEDEN SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. SWEDEN SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. NIGERIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 216. NIGERIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 217. NIGERIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 218. NIGERIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 219. NIGERIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 220. NIGERIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 221. NIGERIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. NIGERIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. EGYPT SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 224. EGYPT SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 225. EGYPT SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 226. EGYPT SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 227. EGYPT SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. EGYPT SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. EGYPT SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. EGYPT SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. TURKEY SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 232. TURKEY SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 233. TURKEY SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 234. TURKEY SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 235. TURKEY SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 236. TURKEY SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 237. TURKEY SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. TURKEY SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. ISRAEL SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 240. ISRAEL SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 241. ISRAEL SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 242. ISRAEL SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 243. ISRAEL SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 244. ISRAEL SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 245. ISRAEL SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. ISRAEL SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. NORWAY SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 248. NORWAY SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 249. NORWAY SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 250. NORWAY SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 251. NORWAY SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 252. NORWAY SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 253. NORWAY SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. NORWAY SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. POLAND SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 256. POLAND SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 257. POLAND SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 258. POLAND SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 259. POLAND SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 260. POLAND SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 261. POLAND SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. POLAND SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. SWITZERLAND SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 264. SWITZERLAND SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 265. SWITZERLAND SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 266. SWITZERLAND SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 267. SWITZERLAND SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 268. SWITZERLAND SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 269. SWITZERLAND SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. SWITZERLAND SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 272. ASIA-PACIFIC SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 274. ASIA-PACIFIC SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 276. ASIA-PACIFIC SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 277. ASIA-PACIFIC SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. ASIA-PACIFIC SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. ASIA-PACIFIC SODIUM PHENYLBUTYRATE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 280. ASIA-PACIFIC SODIUM PHENYLBUTYRATE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 281. CHINA SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 282. CHINA SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 283. CHINA SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 284. CHINA SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 285. CHINA SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 286. CHINA SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 287. CHINA SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. CHINA SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. INDIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 290. INDIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 291. INDIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 292. INDIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 293. INDIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 294. INDIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 295. INDIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. INDIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 297. JAPAN SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 298. JAPAN SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 299. JAPAN SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 300. JAPAN SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 301. JAPAN SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 302. JAPAN SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 303. JAPAN SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 304. JAPAN SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 305. AUSTRALIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 306. AUSTRALIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 307. AUSTRALIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 308. AUSTRALIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 309. AUSTRALIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 310. AUSTRALIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 311. AUSTRALIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 312. AUSTRALIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 313. SOUTH KOREA SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 314. SOUTH KOREA SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 315. SOUTH KOREA SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 316. SOUTH KOREA SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 317. SOUTH KOREA SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 318. SOUTH KOREA SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 319. SOUTH KOREA SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 320. SOUTH KOREA SODIUM PHENYLBUTYRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 321. INDONESIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 322. INDONESIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 323. INDONESIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 324. INDONESIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 325. INDONESIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 326. INDONESIA SODIUM PHENYLBUTYRATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 327.

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Sodium Phenylbutyrate market report include:
  • Horizon Therapeutics plc
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Apotex Inc.
  • Viatris Inc.
  • Amneal Pharmaceuticals LLC
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Aurobindo Pharma Limited

Related Reports

Sodium Phenylbutyrate - Global Strategic Business Report - Product Image

Sodium Phenylbutyrate - Global Strategic Business Report

  • Report
  • 287 Pages
  • Global
From
Urea Cycle Disorder Treatment Market 2025-2029 - Product Image

Urea Cycle Disorder Treatment Market 2025-2029

  • Report
  • 209 Pages
  • Global
From
Urea Cycle Disorders Treatment Market Report 2025 - Product Image

Urea Cycle Disorders Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Urea Cycle Disorder Treatment - Global Strategic Business Report - Product Image

Urea Cycle Disorder Treatment - Global Strategic Business Report

  • Report
  • 381 Pages
  • Global
From
Hyperammonemia Medication Market by Product Type (Ammonia Scavengers, Antibiotics), Route (Intramuscular, Intravenous, Oral), Form, Distribution Channel, Patient Type - Global Forecast 2025-2030 - Product Image

Hyperammonemia Medication Market by Product Type (Ammonia Scavengers, Antibiotics), Route (Intramuscular, Intravenous, Oral), Form, Distribution Channel, Patient Type - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.